Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00446134 · ClinicalTrials.gov registry record · Phase 2
Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)
A Phase 2 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 2
- Development phase
- 278
- Enrollment target
NCT00446134 is a Phase 2 study that has completed, run by Bausch Health Americas. The registered enrollment target is 278 participants.
The verdict
NCT00446134, a Phase 2 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 278 participants
- Enrollment target
Study Summary
The objective of the study is to select an optimal dose of taribavirin by comparing the efficacy and safety of 3 taribavirin dose levels, 20, 25, and 30 mg/kg/day, versus ribavirin 800 to 1400 mg/day based on body weight, both administered in combination with peginterferon alfa-2b to therapy-naive patients with chronic Hepatitis C Virus (HCV) genotype 1 infection.
Interventions
- DRUG Ribavirin
- DRUG Taribavirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 278 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00446134
The ClinicalTrials.gov registry entry for NCT00446134 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 278 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ribavirin is the first listed.
NCT00446134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00446134 about?
NCT00446134 is a clinical study titled "Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)". The objective of the study is to select an optimal dose of taribavirin by comparing the efficacy and safety of 3 taribavirin dose levels, 20, 25, and 30 mg/kg/day, versus ribavirin 800 to 1400 mg/day based on body weight, both administered in combination with peginterferon alfa-2b to therapy-naive p...
What is the current status of trial NCT00446134?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 278 participants. The study started on 2007-03. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00446134?
The interventions under investigation include: Ribavirin (DRUG), Taribavirin (DRUG).
Who is sponsoring clinical trial NCT00446134?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.